ライフサイエンスコーパス: caspofungin

1 1 and of Sko1-dependent genes in response to caspofungin.

2 ved amphotericin B, and from 0 that received caspofungin.

3 bloodstream isolates of C. guilliermondii to caspofungin.

4 associated amphotericin B, voriconazole, and caspofungin.

5 s were studied with either amphotericin B or caspofungin.

6 ced in vitro and in vivo susceptibilities to caspofungin.

7 omplete inhibition of growth) for the MIC of caspofungin.

8 y to voriconazole, and low susceptibility to caspofungin.

9 ates of known high and low susceptibility to caspofungin.

10 atistical criteria for the noninferiority of caspofungin.

11 al dialysis and the first to be treated with caspofungin.

12 zole antifungals, but had elevated MICs with caspofungin.

13 95%), which were particularly susceptible to caspofungin.

14 lay enhanced sensitivity to nikkomycin Z and caspofungin.

15 at high doses of echinocandins, most usually caspofungin.

16 herefore optimize the antifungal activity of caspofungin.

17 he blind and receive preemptive therapy with caspofungin.

18 susceptibility and resistance of Candida to caspofungin.

19 gate marker to predict S and R of Candida to caspofungin.

20 trated with NSC319726 and azoles, as well as caspofungin.

21 pression response to cell wall inhibition by caspofungin.

22 iclofenac showed increased susceptibility to caspofungin.

23 ICs was strongest for fluconazole (0.94) and caspofungin (0.88).

24 0.5/2 (88.3%); anidulafungin, 0.5/2 (97.4%); caspofungin, 0.12/0.5 (98.0%); and micafungin, 0.25/1 (9

25 g/ml of anidulafungin (621 isolates tested), caspofungin (1,447 isolates tested), and micafungin (539

26 ntraperitoneally [i.p.] once a day [QD]), or caspofungin (2 mg/kg i.p. QD), and samples were collecte

27 nsisted of monotherapy of fluconazole (60%), caspofungin (24%), voriconazole (8%), or liposomal ampho

28 8 isolates), amphotericin (29 isolates), and caspofungin (29 isolates).

29 go detectable phosphorylation in response to caspofungin; 3) SKO1 transcript levels are induced by ca

30 254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates), and micafungin (102 isolates

31 Preincubation with caspofungin (32 microg/mL for R. oryzae; 0.0625 microg/m

32 icrog disk (for all except zygomycetes), BBL caspofungin 5-microg disk, and amphotericin B 10-microg

33 azole 1- and 10-microg disks, two sources of caspofungin 5-microg disks [BBL and Oxoid], and posacona

34 eptibility was determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, p

35 ta and caspofungin (85.3%) and C. krusei and caspofungin (54.5%).

36 arisons, with the exception of C. krusei and caspofungin (81.8%).

37 sults with the exceptions of C. glabrata and caspofungin (85.3%) and C. krusei and caspofungin (54.5%

38 en the Vitek 2 system and BMD were 99.8% for caspofungin, 98.2% for micafungin, and 98.1% for posacon

39 nikkomycin Z (a chitin synthase inhibitor), caspofungin (a beta-1,3-glucan synthase inhibitor), or F

40 ng was detected after mice were treated with caspofungin, a beta-1,3-glucan synthase inhibitor that i

41 Caspofungin, a member of the new echinocandin class of c

42 ent does not describe guidelines for testing caspofungin acetate (MK-0991) and other echinocandins ag

43 ubjects (five for each of the five different caspofungin acetate concentrations).

44 zole, and voriconazole) and the echinocandin caspofungin acetate for 100 isolates of Candida spp.

45 Caspofungin acetate given intravenously as a 70-mg loadi

46 Efficacy of caspofungin acetate in a patient with life-threatening C

47 Caspofungin acetate was injected intravitreally in the l

48 ly functionalized antifungal agent CANCIDAS (caspofungin acetate, 2) is described, starting from the

49 Caspofungin acetate, a new antifungal agent with minimal

50 osinophil-mediated mechanism for paradoxical caspofungin activity and support the future investigatio

51 There was no significant change in caspofungin activity over the 4-year study period.

52 We determined the MICs of micafungin and caspofungin against 315 invasive clinical (bloodstream a

53 We determined the in vitro activity of caspofungin against 8,197 invasive (bloodstream or steri

54 procedure at present for in vitro testing of caspofungin against Aspergillus spp.

55 The relatively low efficacy of caspofungin against C. neoformans may result from reduce

56 nation of MICs (FMICs) of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.

57 determination of MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp. th

58 cineurin inhibitor FK506 in combination with caspofungin against echinocandin resistant C. lusitaniae

59 506 has synergistic fungicidal activity with caspofungin against echinocandin resistant isolates.

60 agar media that contain serial dilutions of caspofungin (agar dilution).

61 Perturbation with the cell wall inhibitor caspofungin also has distinct gene expression impact in

62 restingly, treatment of wild-type cells with caspofungin also increased MBL binding to C. neoformans.

63 ance for emergence of in vitro resistance to caspofungin among invasive Candida spp. isolates is indi

64 Fluconazole, caspofungin, amphotericin B, or lipid formulation of amp

65 on factor mutants that are hypersensitive to caspofungin, an inhibitor of beta-1,3-glucan synthase.

66 f Pneumocystis pneumonia that treatment with caspofungin, an inhibitor of beta-1,3-glucan synthesis,

67 ical cutoff values (ECVs) of 0.12 mug/ml for caspofungin and 0.03 mug/ml for micafungin to differenti

68 the Neo-Sensitabs assay for testing 5-microg caspofungin and 1-microg voriconazole posaconazole table

69 overall success rates were 33.9 percent for caspofungin and 33.7 percent for liposomal amphotericin

70 as evaluated in 1095 patients (556 receiving caspofungin and 539 receiving liposomal amphotericin B).

71 hypersensitivity to the cell wall inhibitor caspofungin and a shallow cell wall structure.

72 p90 promoter resulted in hypersensitivity to caspofungin and abolition of the paradoxical effect (res

73 Colorimetric MICs of caspofungin and amphotericin B corresponded to the first

74 Caspofungin and amphotericin B inhibited 93% and 89% of

75 ed essentially normal responses to the drugs caspofungin and amphotericin.

76 l cutoff value (ECV) of 0.12 mug/ml for both caspofungin and anidulafungin to differentiate wild-type

77 r intermediate [I] or resistant [R]) to both caspofungin and anidulafungin, 52 (83.8%) contained a mu

78 in or with preexposure to the combination of caspofungin and anti-beta-glucan monoclonal antibody, us

79 solates, from 0.5% (2001) to 3.1% (2009) for caspofungin and C. parapsilosis, from 0.4% (2004) to 1.8

80 lates to the combination of voriconazole and caspofungin and clinical outcome.

81 s oryzae to itraconazole, amphotericin B, or caspofungin and exposure of Aspergillus fumigatus to vor

82 ere established after 24 h of incubation for caspofungin and micafungin and after 48 h of incubation

83 The Vitek 2 system reliably determined caspofungin and micafungin MICs among Candida spp. and p

84 EAs) between the Vitek 2 and BMD methods for caspofungin and micafungin were 99.5% and 98.6%, respect

85 e (either intermediate or resistant) to both caspofungin and micafungin, 54 (90.0%) contained a mutat

86 isolates of Candida spp. were tested against caspofungin and micafungin.

87 sensitive to the cell wall-active antifungal caspofungin and other cell wall stress inducers, and its

88 We investigated whether caspofungin and other echinocandins have immune-enhancin

89 The addition of caspofungin and voriconazole decreased growth of Candida

90 Genes responsive to ketoconazole, caspofungin, and 5-FC were indicative of the drug-specif

91 in response to ketoconazole, amphotericin B, caspofungin, and 5-fluorocytosine (5-FC), respectively.

92 of 3 commonly used antifungals: fluconazole, caspofungin, and amphotericin B.

93 hree FDA-approved echinocandins (micafungin, caspofungin, and anidulafungin).

94 ed the in vitro activities of anidulafungin, caspofungin, and micafungin against 5,346 invasive (bloo

95 ed the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 isolates of Aspe

96 erpretive MIC breakpoints for anidulafungin, caspofungin, and micafungin against Candida species.

97 posaconazole, amphotericin B, anidulafungin, caspofungin, and micafungin against invasive, unique pat

98 (CLSI) BMD method M27-A3 for anidulafungin, caspofungin, and micafungin susceptibility testing of 13

99 The CLSI-developed ECVs for anidulafungin, caspofungin, and micafungin were applied to 15,269 isola

100 amphotericin B, voriconazole, posaconazole, caspofungin, and micafungin were assessed for 290 clinic

101 to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin were determined by CLSI brot

102 ICs to FLC and echinocandins (anidulafungin, caspofungin, and micafungin) and FKS1 and FKS2 gene sequ

103 ited by < or = 2 microg/ml of anidulafungin, caspofungin, and micafungin, respectively) were as follo

104 non-WT isolates per year for anidulafungin, caspofungin, and micafungin, respectively, were as follo

105 is shown in parentheses) for anidulafungin, caspofungin, and micafungin, respectively, were as follo

106 %, and 8.0% were resistant to anidulafungin, caspofungin, and micafungin, respectively.

107 f Candida sp. strains against anidulafungin, caspofungin, and micafungin, using CLSI M27-A3 broth mic

108 or fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin, while a provisional suscept

109 o voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin.

110 silosis to the echinocandins, anidulafungin, caspofungin, and micafungin.

111 ida spp. to the echinocandins anidulafungin, caspofungin, and micafungin.

112 lates of Candida spp. against anidulafungin, caspofungin, and micafungin.

113 B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin) and interpre

114 azole resistant, and all were susceptible to caspofungin, anidulafungin, and micafungin.

115 Interpretive disk diffusion breakpoints for caspofungin are proposed by evaluating 762 isolates of C

116 candin drugs (micafungin, anidulafungin, and caspofungin) are the preferred choice to treat a range o

117 able invasive candidiasis in the placebo and caspofungin arms was 16.7% (14/84) and 9.8% (10/102), re

118 d, double-blind, placebo-controlled trial of caspofungin as antifungal prophylaxis in 222 adults who

119 rial, we assessed the efficacy and safety of caspofungin as compared with liposomal amphotericin B as

120 on for amphotericin B and 50% inhibition for caspofungin as measured by a fluorescent signal.

121 nd recommend amphotericin B, fluconazole, or caspofungin as the primary therapeutic option.

122 Etest identified all 7 mutant strains using caspofungin as the reagent.

123 onazole-resistant isolates were inhibited by caspofungin at concentrations that can be exceeded by st

124 Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 m

125 ested were susceptible to amphotericin B and caspofungin, but 11% were resistant or dose-dependently

126 ole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and amphotericin B (A) were tested with

127 ceptibility testing for the antifungal agent caspofungin can be performed using flow cytometry (FC).

128 ata exists regarding the pharmacodynamics of caspofungin (CAS) during invasive pulmonary aspergillosi

129 10 different species obtained as part of the caspofungin clinical trials.

130 ncentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberran

131 f the paradoxical effect (resistance at high caspofungin concentrations).

132 s that were treated with both diclofenac and caspofungin contained significantly fewer biofilm cells

133 now commonly treated with the echinocandins caspofungin (CSF) or micafungin (MCF).

134 ecies-specific ECVs for anidulafungin (ANF), caspofungin (CSF), micafungin (MCF), fluconazole (FLC),

135 lates at <or=1 microg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 microg/ml.

136 systemic administration of voriconazole and caspofungin despite poor in vitro activity of voriconazo

137 to the zone diameters observed with 5-microg caspofungin disks produced by two different disk manufac

138 nt who should have received a higher dose of caspofungin due to his obesity.

139 to predict the susceptibility of Candida to caspofungin due to unacceptably high interlaboratory var

140 Overall, the agreement between caspofungin Etest MICs and broth dilution values was hig

141 However, caspofungin exhibited potent in vitro activity at therap

142 n ergosterol biosynthesis and sterol uptake; caspofungin exposure affected genes involved in cell wal

143 PMN-induced damage increased after caspofungin exposure and was further augmented by the ad

144 s, and Scedosporium apiospermum hyphae after caspofungin exposure.

145 d Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole

146 aconazole, posaconazole, amphotericin B, and caspofungin for 383 invasive Candida sp. isolates from S

147 sted were inhibited (MIC50) and the MIC90 of caspofungin for all eight Candida species were within 1

148 on, with the MICs against amphotericin B and caspofungin for all species.

149 0%) with the MICs of both amphotericin B and caspofungin for all species.

150 potential use of calcineurin inhibitors and caspofungin for emerging drug-resistant C. lusitaniae in

151 from patients treated with an echinocandin (caspofungin) for which the MICs were > 2 microg/ml (two

152 The first of the class to be licensed was caspofungin, for refractory invasive aspergillosis (abou

153 owth of C. glabrata and C. tropicalis, while caspofungin generally favored significant growth of all

154 seven days after therapy was greater in the caspofungin group (92.6 percent vs. 89.2 percent, P=0.05

155 y discontinuation occurred less often in the caspofungin group than in the amphotericin B group (10.3

156 s, a higher proportion of those treated with caspofungin had a successful outcome (51.9 percent vs. 2

157 Caspofungin has excellent in vitro activity against inva

158 The new triazoles and caspofungin have excellent in vitro activity against a v

159 1 regulators were identified from a panel of caspofungin-hypersensitive protein kinase-defective muta

160 MIC testing with caspofungin identified all mutant strains.

161 s determined after intravitreal injection of caspofungin in a mouse model to assess its safety profil

162 tes, ranging from 2.1% isolates resistant to caspofungin in Baltimore to 3.1% isolates resistant to a

163 in; 3) SKO1 transcript levels are induced by caspofungin in both wild-type and hog1 mutant strains; a

164 Results of studies of caspofungin in candidaemia and invasive candidiasis sugg

165 be one factor that leads to falsely elevated caspofungin in vitro susceptibility results and that thi

166 onazole, three with micafungin, and one with caspofungin) including 2,792 patients were identified.

167 of A. fumigatus, but not S. prolificans, to caspofungin induced expression of Dectin-1 by PMN.

168 Caspofungin-induced unmasking caused approximately fourf

169 Unexpectedly, caspofungin induces many of the same genes that are repr

170 sko1 mutants are defective in expression of caspofungin-inducible genes that are not induced by osmo

171 All three new triazoles and caspofungin inhibited >95% of Aspergillus spp. at <or=1

172 crog/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at <or=0.5 microg/m

173 The echinocandin antifungal caspofungin inhibits synthesis of cell wall beta-1,3-glu

174 Caspofungin inhibits the synthesis of 1,3-beta-D-glucan,

175 Caspofungin is a safe antifungal agent at vitreal concen

176 Caspofungin is a synthetic echinocandin antifungal agent

177 Caspofungin is as effective as and generally better tole

178 Caspofungin is being used increasingly as therapy for in

179 lux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporter

180 183 filamentous isolates to amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazol

181 ntifungals posaconazole, amphotericin B, and caspofungin, likely through increasing antifungal penetr

182 se events are generally mild, including (for caspofungin) local phlebitis, fever, abnormal liver func

183 Caspofungin may be useful in the treatment of C. albican

184 ], 0.007 microg/ml; MEC90, 0.015 microg/ml), caspofungin (MEC50, 0.015 microg/ml; MEC90, 0.03 microg/

185 Caspofungin MIC values and species-specific interpretive

186 east isolates (all Candida glabrata) showing caspofungin MIC values of >or=0.5 microg/ml were further

187 Caspofungin MIC values were compared with those of anidu

188 acceptably high interlaboratory variation in caspofungin MIC values, we evaluated the use of micafung

189 acceptably high interlaboratory variation of caspofungin MIC values.

190 In general, caspofungin MIC-2 and MEC pairs were comparable with bot

191 Caspofungin (MIC at which 90% of isolates tested are sus

192 are inhibited [MIC(50)], >128 microg/ml) and caspofungin (MIC(50), >8 microg/ml).

193 resistant to fluconazole were susceptible to caspofungin (MIC(90), 0.06 microg/ml) and flucytosine (M

194 ml), micafungin (MIC(90), 0.12 microg/ml) or caspofungin (MIC(90), 0.25 microg/ml).

195 (MIC50, 0.06 microg/ml; MIC90, 2 microg/ml), caspofungin (MIC50, 0.03 microg/ml; MIC90, 0.25 microg/m

196 MIC of < or =2 microg/ml) and comparable to caspofungin (MIC50/MIC90, 0.03/0.25 mug/ml; 99% inhibite

197 t ranged from 99.3% (anidulafungin) to 100% (caspofungin, micafungin) and interlaboratory reproducibi

198 Echinocandins (caspofungin, micafungin, and anidulafungin) exert their

199 gs that showed the most potent activity were caspofungin, micafungin, and terbinafine, while amphoter

200 , posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine.

201 MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also dete

202 formed against 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posa

203 tudy of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against

204 for C. krusei isolates, as all isolates had caspofungin MICs above the threshold for resistance meas

205 All C. glabrata isolates had caspofungin MICs of >/=0.5 mug/ml, the clinical breakpoi

206 Of the 25 isolates with caspofungin MICs of >1 microg/ml, 12 isolates were C. pa

207 n MICs of >2 microg/ml, but all demonstrated caspofungin MICs of >2 microg/ml.

208 sis isolates had wild-type FKS sequences and caspofungin MICs of 0.5 to 1 microg/ml, but 4/5 had mica

209 us untreated polystyrene microtiter trays on caspofungin MICs using 209 isolates of four Candida spec

210 Strains for which anidulafungin and caspofungin MICs were >/=0.5 mug/ml and for which micafu

211 Among the 11 isolates for which caspofungin MICs were >/=2 microg/ml, eight were account

212 Caspofungin MICs were also determined using the commerci

213 d from resistant/non-wild-type isolates when caspofungin MICs were measured using untreated polystyre

214 identified as susceptible or resistant when caspofungin MICs were measured with treated or untreated

215 us, A. nidulans, A. niger, and A. terreus to caspofungin (MICs and minimum effective concentrations [

216 ONCLUSIONS.: Combination of voriconazole and caspofungin might be considered preferable therapy for s

217 he Etest for testing the susceptibilities to caspofungin (MK-0991) of 726 isolates of Candida spp. wa

218 The echinocandin derivative caspofungin (MK-0991, L-743,872) inhibits 1,3-beta-d-glu

219 isolates of C. guilliermondii tested against caspofungin, most were inhibited by < or =2 microg/ml (9

220 luded monotherapy with fluconazole (n = 39), caspofungin (n = 16), and a polyene-based product (n = 1

221 ant recipients who received voriconazole and caspofungin (n=40) as primary therapy for invasive asper

222 osaconazole, ravuconazole, voriconazole, and caspofungin of 601 invasive isolates of Candida glabrata

223 ICs or minimum effective concentrations (for caspofungin only), and the categorical agreement were si

224 With caspofungin or anidulafungin administration into the hea

225 catheters retrieved from rats receiving only caspofungin or diclofenac.

226 posaconazole exhibits in vitro synergy with caspofungin or FK506 against drug susceptible or resista

227 With either caspofungin or micafungin as the test reagent, the CLSI

228 with the beta-1,3 glucan synthase inhibitor caspofungin or the calcineurin inhibitor FK506 against t

229 age occurring with or without preexposure to caspofungin or with preexposure to the combination of ca

230 abrata that were resistant to anidulafungin, caspofungin, or micafungin were shown to have fks mutati

231 Caspofungin- or micafungin-treated conidia and germlings

232 ol and amphotericin (P<.001) and control and caspofungin (P<.001) arms.

233 We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, i

234 e (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant.

235 er 2010 to October 2012 (Period 2), targeted caspofungin prophylaxis was administered to all recipien

236 en Aspergillus fumigatus are associated with caspofungin prophylaxis.

237 ifungal susceptibility of Candida species to caspofungin provided results equivalent to those obtaine

238 Growth at 4 microg/mL of caspofungin reduced both glucan linkages in both strains

239 At the vitreal concentration of 41 muM, caspofungin reduced the amplitudes of the a-waves, b-wav

240 surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates

241 f >/=0.5 mug/ml, the clinical breakpoint for caspofungin resistance in this species, measured using t

242 from wild type, but testing C. glabrata with caspofungin should be approached cautiously.

243 ntifungal agents, including voriconazole and caspofungin, show promise in the treatment of potentiall

244 ing RPG appears to be useful for determining caspofungin susceptibilities of Candida species.

245 atory variability is observed in testing the caspofungin susceptibility of Candida species by both th

246 Fewer patients who received caspofungin sustained a nephrotoxic effect (2.6 percent

247 roducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all condit

248 y variability was seen in the results of the caspofungin tests.

249 e 1) sko1 mutants are much more sensitive to caspofungin than hog1 mutants; 2) Sko1 does not undergo

250 al surface chitin in A. fumigatus induced by caspofungin that was associated with airway eosinophil r

251 For amphotericin B and caspofungin, the FMIC end point was the lowest concentra

252 ted experience with combination triazole and caspofungin therapy has been very limited; however, the

253 For higher resistance levels, empirical caspofungin therapy is preferred.

254 For prevalences exceeding 60%, empirical caspofungin therapy is reasonable.

255 Empirical caspofungin therapy is the most effective strategy but i

256 ant patients diagnosed with IA that received caspofungin therapy when compared with azole-treated pat

257 rgillata infection while on posaconazole and caspofungin therapy.

258 enter C patient who responded to then failed caspofungin therapy.

259 population with concurrent voriconazole and caspofungin therapy.

260 For caspofungin to be reasonable at a prevalence of 10%, its

261 cells were treated with a sublethal dose of caspofungin to increase surface 1,3-beta-glucan exposure

262 could be useful in combination therapy with caspofungin to treat C. albicans biofilm-associated infe

263 he Etest and CLSI results ranged from 90.2% (caspofungin) to 93.2% (anidulafungin).

264 e EUCAST and CLSI results ranged from 89.5% (caspofungin) to 99.2% (micafungin), whereas the EA betwe

265 Caspofungin-treated C. albicans was fully able to suppre

266 itment and inhibition of fungal clearance in caspofungin-treated mice with IA required RAG1 expressio

267 More importantly, caspofungin treatment of mice with IA resulted in a patt

268 or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing systemic and intr

269 Nanoscopic imaging of caspofungin-unmasked C. albicans cell walls revealed tha

270 s and resulted in a significant reduction of caspofungin usage, with an overall cost savings of 1,729

271 11; P < .001), and prior voriconazole and/or caspofungin use (OR, 4.41; P = .033) were associated wit

272 redict the susceptibility of Candida spp. to caspofungin using reference methods and species-specific

273 s determined in cells grown with and without caspofungin, using affinity-purified antisera and gold p

274 ts treated with combination voriconazole and caspofungin (V/C) salvage therapy for refractory coccidi

275 For Candida spp., the MIC for caspofungin was defined as the concentration at which th

276 iables on in vitro susceptibility testing of caspofungin was examined with 694 isolates of Candida al

277 of this method, susceptibility testing using caspofungin was performed using 73 isolates of eight dif

278 Caspofungin was safe and tended to reduce the incidence

279 d as a membrane-active antifungal agent, and caspofungin was selected as a cell wall-active agent.

280 Caspofungin was tested in parallel against all isolates.

281 The MIC for caspofungin was the lowest concentration of drug that di

282 The endpoint for reading caspofungin was the minimum effective concentration (MEC

283 Overall, caspofungin was very active against Candida (MIC50/MIC90

284 us isolates with decreased susceptibility to caspofungin were identified.

285 their correlation with either MICs or MECs (caspofungin) were superior on MH agar (91 to 100% versus

286 icacy of the combination of voriconazole and caspofungin when used as primary therapy for invasive as

287 nd after treatment with the antimycotic drug caspofungin, which alters glucan exposure.

288 vitro susceptibilities to amphotericin B and caspofungin, which correlated with clinical failure of t